Please assess the completion status of the following clinical trial:

Trial Title: Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has stage 1-5 chronic kidney disease (CKD) as defined by the Kidney Disease Outcomes Quality Initiative (K/DOQI) with proteinuria, including any of the following aetiologies: immunoglobulin (IgA) nephropathy, polycystic kidney disease (PCKD), congenital abnormalities, reflux nephropathy, focal segmental glomerulosclerosis, minimal change nephropathy, and membranous nephropathy.~Exclusion Criteria:~* Required peritoneal dialysis or haemodialysis.~* Has kidney disease due to diabetes mellitus, vasculitis, systemic lupus erythematosus, or known renovascular disease; antiglomerular basement membrane disease; or is on immunosuppressive medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sitaxsentan (Type: EXPERIMENTAL): Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
- Nifedipine (Type: ACTIVE_COMPARATOR): Nifedipine 30 mg extended release tablets, orally administered once daily (open label arm)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for sitaxsentan, orally administered once daily (double blind arm)

Based on this trial design, predict the completion outcome and termination type (if applicable).